Therapy News and Research

RSS

One-third of PsA patients not receiving adalimumab doses to achieve optimal clinical benefit

Data presented today at the European League Against Rheumatism Annual Congress showed that a significant number of patients with psoriatic arthritis (PsA) were not receiving doses of the tumour necrosis factor-alpha (TNFα) inhibitor adalimumab necessary to achieve optimal clinical benefit.

12 Jun 2014

New path may lead to powerful adjunctive novel therapy for PTSD treatment

There are currently only two FDA-approved medications for the treatment of posttraumatic stress disorder (PTSD) in the United States. Both of these medications are serotonin uptake inhibitors. Despite the availability of these medications, many people diagnosed with PTSD remain symptomatic, highlighting the need for new medications for PTSD treatment.

12 Jun 2014

DNA methylation identified as potential anti-TNF response biomarker for RA

DNA methylation has been identified as a potential biomarker of response to etanercept and adalimumab in patients with rheumatoid arthritis (RA) according to preliminary results from one of the largest methylome-wide investigations of treatment response to anti-TNF therapies.

12 Jun 2014

Cancer drug offers protection against thrombosis

Case Western Reserve University researchers have discovered that an existing drug used to help cancer patients has the potential to protect thousands of others from the often-deadly impact of vascular clots.

12 Jun 2014

Janssen, Viiv Healthcare to develop single tablet regimen for maintenance treatment of HIV

Janssen R&D Ireland Ltd announced today that they have entered into a collaboration with ViiV Healthcare to develop and commercialize a new single tablet regimen containing Janssen's Non-Nucleoside Reverse Transcriptase Inhibitor rilpivirine (marketed as EDURANT®) and ViiV's Integrase Inhibitor dolutegravir(marketed as TIVICAY®) as the sole active ingredients for the maintenance treatment of people living with Human Immunodeficiency Virus (HIV).

12 Jun 2014

Ferrer recruits first patient in second phase III trial of Ozenoxacin for treatment of impetigo

Ferrer, a privately-held Spanish pharmaceutical company, today announces that the first patient has been recruited into a second phase III trial of Ozenoxacin, formulated as a topical treatment for infectious dermatological conditions in adult and paediatric patients with impetigo. The study is scheduled to complete in Q1, 2015.

12 Jun 2014

TxCell receives Certificate of GMP compliance for cell therapy manufacturing facility in France

TxCell SA, a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that it has been granted Certificate of Good Manufacturing Practice (GMP) compliance for its cell therapy manufacturing facility in Besançon, France.

12 Jun 2014

Researchers study structural aspects of DNA-particle/lipid interface directly using x-ray scattering

Scientists seeking ways to engineer the assembly of tiny particles measuring just billionths of a meter have achieved a new first-the formation of a single layer of nanoparticles on a liquid surface where the properties of the layer can be easily switched.

11 Jun 2014

Molecular mechanisms regulating tumour initiation in skin SCC uncovered

Advanced online publication in Nature: Researchers at the Université libre de Bruxelles, ULB uncover the molecular mechanisms regulating tumour initiation and cancer stem cells functions in skin squamous cell carcinoma.

11 Jun 2014

Auxilium and Prasco introduce authorized generic version of Testim

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, today announced that it has partnered with Prasco, LLC ("Prasco") to introduce an Authorized Generic version of Testim® (testosterone gel).

11 Jun 2014

New research collaboration aims to develop better therapies for autoimmune diseases

Seattle Children's Research Institute and biotechnology company Kineta, Inc. today launched the Alliance for Children's Therapeutics (ACT), a first-of-its-kind pediatric research and funding collaboration designed to speed development of new medications for children and teens with lupus nephritis and other autoimmune diseases like multiple sclerosis, Type 1 diabetes and rheumatoid arthritis.

11 Jun 2014

‘Real-world’ ambrisentan data unveiled

The use of and outcomes with ambrisentan in clinical practice are different to those in clinical trials, reflecting different patient characteristics in the “real world”, say researchers.

11 Jun 2014

Hunterdon Regional Cancer Center offers immuno-therapy clinical trial for lung cancer

According to the American Cancer Society, lung cancer is the second most common cancer among men and women and the leading cause of death in the United States. In 2014, it is estimated that 224,210 people will be diagnosed with lung cancer.

11 Jun 2014

Text messages to smokers' mobile phones help quit smoking

Sending smokers individualized text messages to their mobile phones was found to be twice as effective at helping them quit smoking compared to simply providing self-help materials, according to a study in American Journal of Preventive Medicine.

11 Jun 2014

New prescription weight-loss medication combines antidepressant with addiction medication

A new prescription weight-loss medication that combines a popular antidepressant with a medication for addiction will be reviewed by the Federal Drug Administration (FDA) for potential approval.

11 Jun 2014

AbbVie's ALIGN study underscores patients’ attitudes and adherence toward TNF inhibitors

AbbVie today announced results from its multi-country ALIGN study, which shows that across six chronic immune-mediated inflammatory diseases (IMIDs), adherence to treatment was generally higher in patients being treated with TNF inhibitors compared to patients treated with conventional therapy.

11 Jun 2014

Helix Healthcare Group offers individualized treatment for substance abuse, addiction, mental health issues

Helix Healthcare Group is the first integrated facility in Canada to offer a highly individualized approach in the treatment of substance abuse, addiction and mental health issues.

11 Jun 2014

Conventional proton radiotherapy to fight against cancer

The future face of modern-day anti-cancer therapy based on charged particles like protons could potentially involve using laser accelerators. However, these facilities will need to be reduced in terms of both size and cost compared to conventional ones.

11 Jun 2014

Paradigm shift in new, highly targeted leukaemia therapy

Australian researchers are zeroing in on a promising new approach to killing off cancer cells in patients with leukemia.

11 Jun 2014

Study presents oxytocin as latest treatment target for age-related muscle wasting

Researchers at the University of California, Berkeley, have discovered that oxytocin -- a hormone associated with maternal nurturing, social attachments, childbirth and sex -- is indispensable for healthy muscle maintenance and repair, and that in mice, it declines with age.

11 Jun 2014

Therapy News and Research

One-third of PsA patients not receiving adalimumab doses to achieve optimal clinical benefit

New path may lead to powerful adjunctive novel therapy for PTSD treatment

DNA methylation identified as potential anti-TNF response biomarker for RA

Cancer drug offers protection against thrombosis

Janssen, Viiv Healthcare to develop single tablet regimen for maintenance treatment of HIV

Ferrer recruits first patient in second phase III trial of Ozenoxacin for treatment of impetigo

TxCell receives Certificate of GMP compliance for cell therapy manufacturing facility in France

Researchers study structural aspects of DNA-particle/lipid interface directly using x-ray scattering

Molecular mechanisms regulating tumour initiation in skin SCC uncovered

Auxilium and Prasco introduce authorized generic version of Testim

New research collaboration aims to develop better therapies for autoimmune diseases

‘Real-world’ ambrisentan data unveiled

Hunterdon Regional Cancer Center offers immuno-therapy clinical trial for lung cancer

Text messages to smokers' mobile phones help quit smoking

New prescription weight-loss medication combines antidepressant with addiction medication

AbbVie's ALIGN study underscores patients’ attitudes and adherence toward TNF inhibitors

Helix Healthcare Group offers individualized treatment for substance abuse, addiction, mental health issues

Conventional proton radiotherapy to fight against cancer

Paradigm shift in new, highly targeted leukaemia therapy

Study presents oxytocin as latest treatment target for age-related muscle wasting

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News